A comparative study on level of hepatic steatosis and fibrosis between pre-and post-chelation therapy in patients with chronic lead poisoning

Not Applicable

Completed

• Conditions: steatosis; iver steatosis; chronic lead poisoning; hepatotoxicity; liver fibrosis; hepatitis; Glutathione; Interleukin- 1

• Registration Number: TCTR20191108001
• Lead Sponsor: nit of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2018-05-01
• Study Start: 2019-11-08
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 86

Inclusion Criteria

For Chonic lead poisoning group
- Patients with blood lead level ≥ 70 µg/dl
- Exposed to lead ≥ 1 year
For controlled group
- Patients with blood lead level < 40 µg/dl
- Age-sex matched with participants

Exclusion Criteria

- Chronic HBV infection
- Chonic HCV infection
- Autoimmune hepatitis
- Wilsons disease
- Hemochromatosis
- Alcohol consumption (>= 30 g/day in men, >= 20 g/day in women)
- Prior known exposure to hepatotoxicity drugs within 5 years
- known history of NAFLD
- Diabetes Mellitus

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hepatic steatosis At the study enrollment Controlled Attenuated Parameter (CAP) from fibroscan

Secondary Outcome Measures

Name	Time	Method
Hepatic fibrosis At the study enrollment Liver stiffness from fibroscan